GCP
TNYA icon

GSA Capital Partners’s Tenaya Therapeutics TNYA Stock Holding History

GSA Capital Partners’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Buy
2,669,033
+1,596,122
+149% +$1.21M 0.12% 177
2026
Q1 		$743K Sell
1,072,911
-405,701
-27% -$299K 0.05% 652
2025
Q4 		$1.05M Buy
1,478,612
+1,016,808
+220% +$1.38M 0.09% 332
2025
Q3 		$748K Buy
+461,804
New +$465K 0.06% 590
2024
Q4 		– Sell
-147,932
Closed -$286K – 2032
2024
Q3 		$286K Sell
147,932
-34,130
-19% -$96.4K 0.02% 1241
2024
Q2 		$564K Sell
182,062
-41,989
-19% -$173K 0.04% 880
2024
Q1 		$1.17M Sell
224,051
-246,794
-52% -$1.18M 0.09% 343
2023
Q4 		$1.53M Buy
470,845
+107,352
+30% +$232K 0.13% 214
2023
Q3 		$927K Buy
363,493
+240,082
+195% +$1.01M 0.08% 441
2023
Q2 		$724K Buy
123,411
+35,243
+40% +$205K 0.07% 508
2023
Q1 		$251K Buy
+88,168
New +$248K 0.02% 1129
2022
Q4 		– Sell
-62,666
Closed -$182K – 1892
2022
Q3 		$182K Buy
+62,666
New +$292K 0.02% 1257

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

GSA Capital Partners's TNYA Position: Q2 2026 in Review

GSA Capital Partners increased its Tenaya Therapeutics (TNYA) stake by 149% in Q2 2026, buying an estimated $1.21M and bringing the position to 2,669,033 shares worth $1.97M. The position accounts for 0.12% of the portfolio, ranked #177.

GSA Capital Partners first reported a position in TNYA in Q3 2022 and has held it in 12 quarters since. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • GSA Capital Partners held 2,669,033 shares of Tenaya Therapeutics worth $1.97M as of Q2 2026.
  • GSA Capital Partners bought 1,596,122 Tenaya Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Tenaya Therapeutics made up 0.12% of GSA Capital Partners's portfolio in Q2 2026, its #177 holding.
  • GSA Capital Partners first reported a position in Tenaya Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.